CBD May Reduce Early Nerve Damage Symptoms from Chemotherapy
Cancer patients taking 300 mg daily CBD before and during chemotherapy showed reduced early signs of peripheral neuropathy compared to untreated controls, with no major safety concerns.
Quick Facts
What This Study Found
CBD-treated patients receiving CAPOX or Carbo-Tax chemotherapy showed significantly better high-frequency vibrometry scores compared to controls. CAPOX patients on CBD also reported less cold sensitivity and throat discomfort.
Key Numbers
54 patients recruited. CBD dose: 300 mg/day. Carbo-Tax patients showed the largest vibrometry improvement at 250 Hz (difference: -1.76, 95% CI -2.52 to -1.02). CAPOX patients had lower cold sensitivity (-2.08), discomfort swallowing cold liquids (-2.06), and throat discomfort (-1.81) scores. Side effects: grades 1-2 stomach pain in CAPOX patients.
How They Did This
Prospective study of 54 cancer patients scheduled for oxaliplatin- or paclitaxel-based chemotherapy. Patients received 150 mg CBD oil twice daily (300 mg/day) for 8 days starting 1 day before chemotherapy. Neuropathy was measured by multi-frequency vibrometry and 10 patient-reported outcome measures. Controls came from a similar untreated cohort.
Why This Research Matters
Chemotherapy-induced peripheral neuropathy (CIPN) affects up to a third of cancer patients and has no well-established preventive treatment. If CBD can reduce early neuropathy symptoms, it could improve quality of life during cancer treatment.
The Bigger Picture
CIPN prevention is an unmet need in oncology. This is among the first prospective studies testing CBD specifically for CIPN prevention rather than general cancer pain. The results are promising enough to justify the randomized trial that the authors recommend.
What This Study Doesn't Tell Us
This was not randomized. CBD-treated patients were significantly older than controls, which could confound results. The sample size of 54 is small. Only early symptoms (first cycle) were measured; long-term follow-up is ongoing.
Questions This Raises
- ?Will the neuropathy prevention effect persist across multiple chemotherapy cycles?
- ?Would a randomized, placebo-controlled design confirm these findings?
- ?Is 300 mg/day the optimal CBD dose for CIPN prevention?
Trust & Context
- Key Stat:
- -1.76 vibrometry Z-score improvement at 250 Hz in Carbo-Tax patients
- Evidence Grade:
- Preliminary: non-randomized prospective study with 54 patients and historical controls.
- Study Age:
- Published in 2022, with long-term follow-up ongoing.
- Original Title:
- Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy.
- Published In:
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30(11), 9441-9451 (2022)
- Authors:
- Nielsen, Sebastian W, Hasselsteen, Simone Dyring, Dominiak, Helena Sylow Heilmann, Labudovic, Dejan, Reiter, Lars, Dalton, Susanne Oksbjerg, Herrstedt, Jørn
- Database ID:
- RTHC-04102
Evidence Hierarchy
Enrolls participants and follows them forward in time.
What do these levels mean? →Frequently Asked Questions
Can cancer patients take CBD during chemotherapy?
In this study, 300 mg/day CBD appeared safe with only mild stomach pain as a side effect. However, CBD can interact with certain medications, so any use during chemotherapy should involve the treatment team.
Does CBD prevent nerve damage or just reduce symptoms?
The vibrometry improvements suggest CBD may have a protective effect on nerve function, not just symptom relief. However, this needs confirmation in a larger randomized study.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04102APA
Nielsen, Sebastian W; Hasselsteen, Simone Dyring; Dominiak, Helena Sylow Heilmann; Labudovic, Dejan; Reiter, Lars; Dalton, Susanne Oksbjerg; Herrstedt, Jørn. (2022). Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30(11), 9441-9451. https://doi.org/10.1007/s00520-022-07312-y
MLA
Nielsen, Sebastian W, et al. "Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy.." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. https://doi.org/10.1007/s00520-022-07312-y
RethinkTHC
RethinkTHC Research Database. "Oral cannabidiol for prevention of acute and transient chemo..." RTHC-04102. Retrieved from https://rethinkthc.com/research/nielsen-2022-oral-cannabidiol-for-prevention
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.